BEONE
LIVE

Serial Number

98850900

Owner

BeiGene Switzerland GMBH

Attorney

Kristen S. Ruisi

Filing Date

Nov 13, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BEONE Trademark

Serial Number: 98850900

BEONE is a trademark filed by BeiGene Switzerland GMBH on November 13, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

BeiGene Switzerland GMBH

Aeschengraben 27
Basel 4051 , CH

Entity Type: 16

BEONE MEDICINES I GMBH (2 trademarks)

AESCHENGRABEN 27
BASEL 4051 , CH

Entity Type: 16

Trademark Details

Filing Date

November 13, 2024

Registration Date

Not Registered

Published for Opposition

December 2, 2025

Goods & Services

Telemedicine services; health care; convalescent home services; physical therapy services; health counseling; pharmacy advice, namely, pharmaceutical advice

Research and development of new products for others; technological research in the field of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical research; scientific research in the nature of conducting clinical trials for others for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological research; quality control for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; electronic data storage; material testing; cloud computing featuring software for use in database management, word processing, spreadsheet management, tracking; packaging design

Pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemico-pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; drugs in the nature of pharmaceutical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; biological preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for pharmaceutical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; medicines for human purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; chemical preparations for medical purposes for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Injectable pharmaceuticals for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; crude drugs in the nature of pharmaceutical preparations for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases; Biochemical preparations for medical use for the treatment and prevention of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Custom manufacturing services in the nature of chemical processing and production of medicines and pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases, rheumatoid arthritis, cardiovascular diseases and infectious diseases

Filing History

TEAS STATEMENT OF USE RECEIVED
Jan 30, 2026 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jan 27, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 2, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 2, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 26, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 4, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 8, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 30, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 30, 2025 TROA
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 10, 2025 ASGN
ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Jul 9, 2025 ASCK
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jun 27, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jun 27, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 30, 2025 GNRN
NON-FINAL ACTION E-MAILED
Mar 30, 2025 GNRT
NON-FINAL ACTION WRITTEN
Mar 30, 2025 CNRT
ASSIGNED TO EXAMINER
Mar 30, 2025 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Mar 30, 2025 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 30, 2025 NWOS
NEW APPLICATION ENTERED
Nov 13, 2024 NWAP